
Established Ousheng Pharmaceutical in Chengdu, marking the beginning of GoeGoe Honglin's operations in China.

Relocated manufacturing operations from Chengdu to Beijing and completed Phase I of the Beijing manufacturing facility, establishing Beijing as the company's core manufacturing base.

Obtained 4 Chinese patents for core technologies: ZL200610153091.8, ZL200610113725.7, ZL200610113984.X, and ZL200610114125.2.

Recognized as a “National High-Tech Enterprise (China)” and a “Zhongguancun High-Tech Enterprise,” and has maintained both qualifications ever since.

ALZA Corporation (U.S.A.) presented GoeGoe Honglin with the world's first fully automated mechanical drilling machine for controlled-release tablet testing as a commemorative gift, recognizing its historical significance.

Officially commenced construction of Phase II at the Beijing Huairou Plant, expanding production capacity.

Acquired land in Zhenjiang, Jiangsu Province, and initiated plans for a new manufacturing base.

JUPOPINE®, RoToFier®, and JUPOSHU® successfully passed China's Generic Consistency Evaluation. JUPOPINE® was officially recognized as Nifedipine Controlled-Release Tablets.

Held the groundbreaking ceremony for the Zhenjiang manufacturing facility and officially commenced construction.

JUPOPHON® successfully passed China’s Generic Consistency Evaluation.

Obtained a Chinese utility model patent: ZL202420848264.1.

Completed construction and inaugurated the Zhenjiang manufacturing facility.

Zhenjiang Plant officially commenced production, marking the achievement of full-scale production capacity.

Initiated plans for the Phase II sustained- and controlled-release capsule workshop project.

Commenced construction of the Phase II sustained- and controlled-release manufacturing facility in Zhenjiang, with a projected annual capacity of 2.7 billion tablets and capsules. Initiated planning for Phase III expansion to support future capacity growth.